← All trials
NCT05518149
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2022
- Primary completion
- Oct 22, 2025
- Completion date
- Oct 22, 2025
- First posted
- Aug 26, 2022
- Last posted
- Dec 8, 2022
- Enrollment
- 840
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.